Syndax Pharmaceuticals CEO to present at J.P. Morgan Healthcare Conference on January 12, 2026, livestream available online.
Quiver AI Summary
Syndax Pharmaceuticals has announced that its CEO, Michael A. Metzger, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 3:00 p.m. PT/6:00 p.m. ET, with a live webcast available on the company's website. The company focuses on developing innovative cancer therapies, highlighting its pipeline that includes FDA-approved products such as Revuforj® and Niktimvo™. Syndax is committed to advancing cancer care through various clinical trials and aims to maximize the potential of its therapeutic offerings. More details can be found on its website and social media platforms.
Potential Positives
- Michael A. Metzger's presentation at the prestigious J.P. Morgan Healthcare Conference highlights Syndax's leadership presence in the biopharmaceutical industry.
- The company's FDA-approved therapies, Revuforj® and Niktimvo™, demonstrate its commitment to developing innovative cancer treatments, showcasing significant advancements in the field.
- A live webcast of the presentation allows for wide accessibility and engagement with investors and the public, potentially enhancing the company's visibility and reputation.
Potential Negatives
- None
FAQ
When will Syndax Pharmaceuticals present at the J.P. Morgan Healthcare Conference?
Syndax Pharmaceuticals will present on Monday, January 12, 2026, at 3:00 p.m. PT/6:00 p.m. ET.
Where can I watch the Syndax presentation live?
The live webcast of the presentation will be available in the Investor section of Syndax's website at www.syndax.com.
What is Revuforj® from Syndax Pharmaceuticals?
Revuforj® (revumenib) is an FDA-approved menin inhibitor developed by Syndax Pharmaceuticals.
What other therapies are in Syndax's pipeline?
Syndax's pipeline includes Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the CSF-1 receptor.
How can I contact Syndax Pharmaceuticals for more information?
You can contact Syndax Pharmaceuticals at [email protected] or call 781.684.9827 for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNDX Insider Trading Activity
$SNDX insiders have traded $SNDX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $SNDX stock by insiders over the last 6 months:
- MICHAEL A METZGER (Chief Executive Officer) has made 0 purchases and 2 sales selling 164,841 shares for an estimated $2,651,974.
- DENNIS PODLESAK has made 0 purchases and 3 sales selling 57,600 shares for an estimated $875,099.
- KEITH A. GOLDAN (Chief Financial Officer) sold 1,296 shares for an estimated $12,033
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SNDX Hedge Fund Activity
We have seen 123 institutional investors add shares of $SNDX stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 2,127,580 shares (+100.0%) to their portfolio in Q3 2025, for an estimated $32,732,818
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,879,523 shares (+131.2%) to their portfolio in Q3 2025, for an estimated $28,916,461
- BLACKROCK, INC. removed 1,831,663 shares (-17.5%) from their portfolio in Q3 2025, for an estimated $28,180,135
- SOFINNOVA INVESTMENTS, INC. removed 1,524,440 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,453,509
- MPM BIOIMPACT LLC added 1,375,674 shares (+inf%) to their portfolio in Q3 2025, for an estimated $21,164,744
- NUVEEN, LLC added 1,209,755 shares (+454.7%) to their portfolio in Q3 2025, for an estimated $18,612,080
- SPHERA FUNDS MANAGEMENT LTD. removed 1,183,848 shares (-75.3%) from their portfolio in Q3 2025, for an estimated $18,213,501
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNDX Analyst Ratings
Wall Street analysts have issued reports on $SNDX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/09/2025
- Barclays issued a "Overweight" rating on 11/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
- Stifel issued a "Buy" rating on 09/10/2025
- UBS issued a "Buy" rating on 07/15/2025
To track analyst ratings and price targets for $SNDX, check out Quiver Quantitative's $SNDX forecast page.
$SNDX Price Targets
Multiple analysts have issued price targets for $SNDX recently. We have seen 10 analysts offer price targets for $SNDX in the last 6 months, with a median target of $36.5.
Here are some recent targets:
- Justin Zelin from BTIG set a target price of $56.0 on 12/09/2025
- Etzer Darout from Barclays set a target price of $35.0 on 11/24/2025
- Anupam Rama from JP Morgan set a target price of $33.0 on 11/12/2025
- David Dai from UBS set a target price of $38.0 on 11/04/2025
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $40.0 on 10/27/2025
- Bradley Canino from Stifel set a target price of $44.0 on 09/10/2025
- Corinne Johnson from Goldman Sachs set a target price of $24.0 on 09/05/2025
Full Release
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.
A live webcast of the presentation will be available in the Investor section of the Company's website at www.syndax.com , where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn .
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
SNDX-G
